Revenue Recognition (Tables)

9 Months Ended

Sep. 30, 2020

Revenue from Contract with Customer [Abstract]

Disaggregation of revenue

Revenue is disaggregated by primary geographical market, major product line, and timing of revenue recognition.

In thousands of U.S. dollars ($)	Three Months Ended September 30, 2020						Nine Months Ended September 30, 2020
Products By Geographic Area	Total		U.S.		Rest of World		Total		U.S.		Rest of World
Drug Revenues
Product Sales – Point-in-time	$	228	$	228	$	—	$	609	$	609	$	—
License Fee – Over time	56		—		56		167		—		167
Total Drug Products	284		228		56		776		609		167
Concentrate Products
Product Sales – Point-in-time	14,506		13,470		1,036		44,786		40,295		4,491
License Fee – Over time	490		490		—		1,471		1,471		—
Total Concentrate Products	14,996		13,960		1,036		46,257		41,766		4,491
Net Revenue	$	15,280	$	14,188	$	1,092	$	47,033	$	42,375	$	4,658

In thousands of U.S. dollars ($)	Three Months Ended September 30, 2019						Nine Months Ended September 30, 2019
Products By Geographic Area	Total		U.S.		Rest of World		Total		U.S.		Rest of World
Drug Revenues
Product Sales – Point-in-time	$	98	$	98	$	—	$	112	$	112	$	—
License Fee – Over time	$	68	$	—	68		205		—		205
Total Drug Products	166		98		68		317		112		205
Concentrate Products
Product Sales – Point-in-time	14,746		13,353		1,393		44,010		39,100		4,910
License Fee – Over time	495		495		—		1,485		1,485		—
Total Concentrate Products	15,241		13,848		1,393		45,495		40,585		4,910
Net Revenue	$	15,407	$	13,946	$	1,461	$	45,812	$	40,697	$	5,115

Contract balances

The following table provides information about receivables, contract assets, and contract liabilities from contracts with customers.

In thousands of U.S. dollars ($)	September 30, 2020		December 31, 2019
Receivables, which are included in "Trade and other receivables"	$	4,129	$	4,203
Contract liabilities	$	10,738	$	12,076